A novel mitochondrially-targeted apocynin derivative prevents hyposmia and loss of motor function in the leucine-rich repeat kinase 2 (LRRK2R1441G) transgenic mouse model of Parkinson's disease

Neuroscience Letters

Volumn 583, Issue , 2014, Pages 159-164

  Dranka, Brian P ^a,d   Gifford, Alison ^a   McAllister, Donna ^a   Zielonka, Jacek ^a   Joseph, Joy ^a   O'Hara, Crystal L ^b   Stucky, Cheryl L ^b   Kanthasamy, Anumantha G ^c   Kalyanaraman, Balaraman ^a  

^a FREE RADICAL RESEARCH CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c IOWA STATE UNIVERSITY   (United States)

^d Seahorse Bioscience   (United States)

Author keywords

Apocynin; Hyposmia; Neurodegeneration; Parkinson's disease

Indexed keywords

APOCYNIN; CARBON; LEUCINE RICH REPEAT KINASE 2; ACETOPHENONE DERIVATIVE; LRRK2 PROTEIN, MOUSE; ORGANOPHOSPHORUS COMPOUND; PROTEIN SERINE THREONINE KINASE; TRIPHENYLPHOSPHINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; EXPERIMENTAL TEST; GENOTYPE; HIDDEN TREAT TEST; HYPOSMIA; MALE; MITOCHONDRIAL PERMEABILITY; MITOCHONDRION; MOTOR COORDINATION; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NEUROPATHIC PAIN; NONHUMAN; ODOR; OPEN FIELD TEST; PARKINSON DISEASE; RADIAL ARM MAZE TEST; SMELLING; STIMULUS; ANIMAL; CHEMISTRY; DRUG EFFECTS; GENETICS; METABOLISM; OLFACTION DISORDERS; PATHOPHYSIOLOGY; PSYCHOLOGY; TRANSGENIC MOUSE;

ACETOPHENONES; ANIMALS; MICE, TRANSGENIC; MITOCHONDRIA; MOTOR SKILLS; OLFACTION DISORDERS; ORGANOPHOSPHORUS COMPOUNDS; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES;

EID: 84907997127     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2014.09.042     Document Type: Article

References (26)

1. Doty R.L. Olfaction in Parkinson's disease and related disorders. Neurobiol. Dis. 2012, 26:527-552.
2. Ponsen M.M., Stoffers D., Booij J., van Eck-Smit B.L., Wolters E.Ch., Berendse H.W. Ideopathic hyposmia as a preclinical sign of Parkinson's disease. Ann. Neurol. 2004, 56:173-181.
3. Xiao Q., Chen S., Weidong L. Hyposmia: a possible biomarker of Parkinson's disease. Neurosci. Bull. 2014, 30:134-140.
4. Babizhayev M.A., Deyev A.I., Yegorov Y.E. Olfactory dysfunction and cognitive impairment in age-related neurodegeneration: prevalence to patient selection, diagnostic criteria and therapeutic treatment of aged clients receiving clinical neurology and community-based care. Curr. Clin. Pharmacol. 2011, 6:236-259.
5. Pellaprat J., Ory-Magne F., Canivet F.C., Simonetta-Moreau M., Lotterie J.A., Radji F., Arbus C., Gerdelat A., Chaynes P., Brefel-Courbon C. Deep brain stimulation of the subthalamic nucleus improves pain in Parkinson's disease. Parkinsonism Relat. Disord. 2014, 14. pii:S1353-8020(14)00095-9. 10.1016/j.parkreldis.2014.03.011.
6. Garcia-Ruiz P.J., Chaudhuri K.R., Martinez-Martin P. Non-motor symptoms of Parkinson's disease A review. from the past. J. Neurol. Sci. 2014, 338:30-33.
7. Defazio G., Tinazzi M., Beradelli A. How pain arises in Parkinson's disease?. Eur. J. Neurol. 2013, 20:1517-1523.
8. R1441G) transgenic mouse. Neurosci. Lett. 2013, 549:57-62.
9. Li Y., Liu W., Oo T.F., Wang L., Tang Y., Jackson-Lewis V., Zhou C., Geghman K., Bogdanov M., Przedborski S., Beal M.F., Burke R.E., Li C. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat. Neurosci. 2009, 12:826-828.
10. Anantharam V., Kaul S., Song C., Kanthasamy A., Kanthasamy A.G. Pharmacological inhibition of neuronal NADPH oxidase protects against 1-methyl-4-phenylpyridinium (MPP+)-induced oxidative stress and apoptosis in mesencephalic dopaminergic neuronal cells. Neurotoxicology 2007, 28:988-997.
11. Kelso G.F., Porteous C.M., Hughes G., Ledgerwood E.C., Gane A.M., Smith R.A., Murphy M.P. Prevention of mitochondrial oxidative damage using targeted antioxidants. Ann. N. Y. Acad. Sci. 2002, 959:263-274.
12. Ghosh A., Chandran K., Kalivendi S.V., Joseph J., Antholine W.E., Hillard C.J., Kanthasamy A., Kanthasamy A., Kalyanaraman B. Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model. Free Radic. Biol. Med. 2010, 49:1674-1684.
13. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J. Neurosci. Methods 1994, 53:55-63.
14. Garrison S.R., Dietrich A., Stucky C.L. TRPC1 contributes to light-touch sensation and mechanical responses in low-threshold cutaneous sensory neurons. J. Neurophysiol. 2012, 107:913-922.
15. Frye C.A., Edinger K., Sumida K. Androgen administration to aged male mice increases anti-anxiety behavior and enhances cognitive performance. Neuropsychopharmacology 2008, 33:1049-1061.
16. Park E.S., Gao X., Chung J.M., Chung K. Levels of mitochondrial reactive oxygen species increase in rate neuropathic spinal dorsal horn neurons. Neurosci. Lett. 2006, 391:108-111.
17. Nieto F.R., Cendán C.M., Cañizares F.J., Cubero M.A., Vela J.M., Fernández-Segura E., Baeyens J.M. Genetic inactivation and pharmacological blockade of sigma-1 receptors prevent paclitaxel-induced sensory-nerve mitochondrial abnormalities and neuropathic pain in mice. Mol. Pain 2014, 10:11.
18. Fidanboylu M., Griffiths L.A., Flatters S.J. Global inhibition of reactive oxygen species (ROS) inhibits paclitaxel-induced painful peripheral neuropathy. PLoS ONE 2011, 6:e25212.
19. Ekstrand M.I., Galtr D. The MitoPark mouse - an animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons. Parkinsonism Relat. Disord. 2009, 15S3:S185-S188.
20. Picillo M., Pellecchia M.T., Erro R., Amboni M., Vitale C., Iavarone A., Moccia M., Allocca R., Orefice G., Barone P. The use of University of Pennsylvania Smell Identification Test in the diagnosis of Parkinson's disease in Italy. Neurol. Sci. 2014, 35:379-383.
21. McGeer P.L., McGeer E.G. Glial reactions in Parkinson's disease. Mov. Disord. 2008, 23:474-483.
22. Sherer T.B., Betarbet R., Kim J.H., Greenamyre J.T. Selective microglial activationin the rat rotenone model of Parkinson's disease. Neurosci. Lett. 2003, 341:87-90.
23. Surace M.J., Block M.L. Targeting microglia-mediated neurotoxicity: the potential of NOX2 inhibitors. Cell. Mol. Life Sci. 2012, 69:2409-2427.
24. Ghosh A., Kanthasamy A., Joseph J., Anantharam V., Srivastava P., Dranka B.P., Kalyanaraman B., Kanthasamy A.G. Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease. J. Neuroinflamm. 2012, 9:241.
25. Ronnett G.V., Ramamurthy S., Kleman A.M., Landree L.E., Aja S. AMPK in the brain: its roles in energy balance and neuroprotection. J. Neurochem. 2009, 109(Suppl. 1):17-23.
26. Bichler Z., Lim H.C., Zeng L., Tan E.K. Non-motor and motor features in LRRK2 transgenic mice. PLOS ONE 2013, 8:e70249.